DE69921156D1 - Verwendung von 5ht-6 antagonisten zur behandlung adhd - Google Patents
Verwendung von 5ht-6 antagonisten zur behandlung adhdInfo
- Publication number
- DE69921156D1 DE69921156D1 DE1999621156 DE69921156T DE69921156D1 DE 69921156 D1 DE69921156 D1 DE 69921156D1 DE 1999621156 DE1999621156 DE 1999621156 DE 69921156 T DE69921156 T DE 69921156T DE 69921156 D1 DE69921156 D1 DE 69921156D1
- Authority
- DE
- Germany
- Prior art keywords
- antagonists
- adhd treatment
- adhd
- treatment
- subjects
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9818916.0A GB9818916D0 (en) | 1998-08-28 | 1998-08-28 | Use |
GB9818916 | 1998-08-28 | ||
PCT/EP1999/006218 WO2000012073A1 (en) | 1998-08-28 | 1999-08-25 | Use of 5ht-6 antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69921156D1 true DE69921156D1 (de) | 2004-11-18 |
DE69921156T2 DE69921156T2 (de) | 2005-10-13 |
Family
ID=10838075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69921156T Expired - Lifetime DE69921156T2 (de) | 1998-08-28 | 1999-08-25 | Verwendung von 5ht-6 antagonisten zur behandlung adhd |
Country Status (9)
Country | Link |
---|---|
US (2) | US6380199B1 (de) |
EP (1) | EP1107745B1 (de) |
JP (1) | JP2002523447A (de) |
AT (1) | ATE279181T1 (de) |
AU (1) | AU5624699A (de) |
DE (1) | DE69921156T2 (de) |
ES (1) | ES2230884T3 (de) |
GB (1) | GB9818916D0 (de) |
WO (1) | WO2000012073A1 (de) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
US7071220B2 (en) | 2000-09-18 | 2006-07-04 | Toa Eiyo Ltd. | N-substituted benzothiophenesulfonamide derivatives |
CN1245400C (zh) * | 2000-09-18 | 2006-03-15 | 东亚荣养株式会社 | N-取代苯并噻唑磺胺衍生物 |
CA2428971A1 (en) * | 2000-11-14 | 2003-05-01 | New River Pharmaceuticals Inc. | Conjugates of a therapeutic agent and a peptide carrier |
ITBO20010271A1 (it) * | 2001-05-08 | 2002-11-08 | Giuseppe Cannazza | Metodo per il trattamento e la prevenzione dei disturbi del sistema nervoso centrale associati ad una alterazione della neurotrasmissione gl |
KR20090092832A (ko) | 2001-05-11 | 2009-09-01 | 바이오비트럼 에이비(피유비엘) | 비만, 제 ⅱ 형 당뇨병 및 cns 장애의 치료를 위한 신규한 아릴술폰아미드 화합물 |
US7718650B2 (en) | 2001-05-11 | 2010-05-18 | Biovitrum Ab | Aryl sulfonamide compounds for treating obesity |
CA2445653A1 (en) | 2001-06-11 | 2002-12-19 | Biovitrum Ab | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes |
EP1423106B1 (de) | 2001-08-10 | 2008-12-17 | F. Hoffmann-La Roche Ag | Arylsulfonyl-derivate mit 5-ht 6-rezeptor-affinität |
EP1956004B1 (de) | 2002-03-27 | 2012-06-13 | Glaxo Group Limited | Quinolinverbindungen zur Verwendung als 5-HT6 Liganden |
WO2003095434A1 (en) * | 2002-05-13 | 2003-11-20 | F. Hoffmann-La Roche Ag | Benzoxazine derivatives as 5-ht6 modulators and uses thereof |
EP1513828A1 (de) * | 2002-06-20 | 2005-03-16 | Biovitrum AB | Neue, zur behandlung von obesitas, typ ii-diabetes und zns-erkrankungen geeignete verbindungen |
JP4754821B2 (ja) | 2002-06-20 | 2011-08-24 | プロキシマゲン・リミテッド | 肥満症、ii型糖尿病およびcns障害の治療に有用な新規化合物 |
BRPI0412263B1 (pt) | 2003-07-22 | 2019-10-15 | Arena Pharmaceuticals, Inc. | Derivados de diaril e aril heteroaril uréia, uso e composição farmacêutica contendo os mesmos, bem como processo para preparação da dita composição |
US7767683B2 (en) | 2003-08-18 | 2010-08-03 | H. Lundbeck A/S | Hydrogen succinate salts of trans-4-((1R, 3S)-6-chloro-3-phenylindan-1-YL)-1,2,2-trimethylpiperazine and the use as a medicament |
GB0322629D0 (en) * | 2003-09-26 | 2003-10-29 | Glaxo Group Ltd | Novel compound |
BRPI0513386A (pt) * | 2004-08-09 | 2008-05-06 | Warner Lambert Co | inibidores de reabsorção de norepinefrina de quinoxalinona para o tratamento de distúrbios do sistema nervoso central |
TWI376373B (en) | 2005-02-16 | 2012-11-11 | Lundbeck & Co As H | Crystalline base of a pharmaceutical compound |
TWI453198B (zh) | 2005-02-16 | 2014-09-21 | Lundbeck & Co As H | 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s)-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法 |
MX2008009022A (es) | 2006-01-13 | 2008-09-24 | Wyeth Corp | 1h-indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina. |
WO2008113818A1 (en) * | 2007-03-21 | 2008-09-25 | Glaxo Group Limited | Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome |
EP2158195A1 (de) * | 2007-05-15 | 2010-03-03 | Wyeth LLC | 5- (aminoazacyclyl) -3-sulfonyl-lh- indazole als 5-hydroxytryptamin- 6 liganden zur behandlung von zns-erkrankungen |
CL2008003232A1 (es) | 2007-11-02 | 2009-11-27 | Abbott Gmbh & Co Kg | Compuestos derivados de bencensulfonanilida; composición farmacéutica que los comprende; y uso en el tratamiento de enfermedades del sistema nervioso central, disfunciones cognitivas, esquizofrenia, enfermedades adictivas, enfermedad de alzheimer u obesidad. |
EP2254564A1 (de) | 2007-12-12 | 2010-12-01 | Glaxo Group Limited | Kombinationen mit 3-phenylsulfonyl-8-piperazinyl-1yl-chinolin |
US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
US20110034565A1 (en) | 2008-04-18 | 2011-02-10 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
UA100192C2 (en) * | 2008-11-11 | 2012-11-26 | УАЙТ ЭлЭлСи | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands |
CA2759491A1 (en) | 2009-04-30 | 2010-11-04 | Abbott Gmbh & Co. Kg. | Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
US8343959B2 (en) | 2009-04-30 | 2013-01-01 | Abbott Gmbh & Co. Kg | N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor |
KR20120016639A (ko) | 2009-04-30 | 2012-02-24 | 애보트 게엠베하 운트 콤파니 카게 | 세로토닌 5-ht6 수용체의 조절에 반응하는 장애를 치료하는 데 적합한 n-페닐-(피페라지닐 또는 호모피페라지닐)-벤젠설폰아미드 또는 벤젠설포닐-페닐-(피페라진 또는 호모피페라진) 화합물 |
EP2432770A1 (de) | 2009-04-30 | 2012-03-28 | Abbott GmbH & Co. KG | Benzolsulfonanilidverbindungen zur behandlung von auf serotonin-5-ht6-rezeptormodulation ansprechenden erkrankungen |
WO2012059432A1 (en) | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor |
WO2012059431A1 (en) | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor |
AU2012321345B2 (en) | 2011-10-03 | 2016-03-17 | The University Of Utah Research Foundation | Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
US20160038484A1 (en) * | 2013-04-03 | 2016-02-11 | The University Of Utah Research Foundation | Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
RU2017145976A (ru) | 2015-06-12 | 2019-07-15 | Аксовант Сайенсиз Гмбх | Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна |
US10034859B2 (en) | 2015-07-15 | 2018-07-31 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DZ2376A1 (fr) * | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
GB9801392D0 (en) * | 1998-01-22 | 1998-03-18 | Smithkline Beecham Plc | Novel compounds |
-
1998
- 1998-08-28 GB GBGB9818916.0A patent/GB9818916D0/en not_active Ceased
-
1999
- 1999-08-25 EP EP99942912A patent/EP1107745B1/de not_active Expired - Lifetime
- 1999-08-25 AU AU56246/99A patent/AU5624699A/en not_active Abandoned
- 1999-08-25 WO PCT/EP1999/006218 patent/WO2000012073A1/en active IP Right Grant
- 1999-08-25 DE DE69921156T patent/DE69921156T2/de not_active Expired - Lifetime
- 1999-08-25 US US09/763,742 patent/US6380199B1/en not_active Expired - Fee Related
- 1999-08-25 AT AT99942912T patent/ATE279181T1/de not_active IP Right Cessation
- 1999-08-25 ES ES99942912T patent/ES2230884T3/es not_active Expired - Lifetime
- 1999-08-25 JP JP2000567191A patent/JP2002523447A/ja active Pending
-
2002
- 2002-03-13 US US10/099,199 patent/US6627661B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE279181T1 (de) | 2004-10-15 |
WO2000012073A1 (en) | 2000-03-09 |
EP1107745B1 (de) | 2004-10-13 |
US6627661B2 (en) | 2003-09-30 |
US20020094979A1 (en) | 2002-07-18 |
US6380199B1 (en) | 2002-04-30 |
AU5624699A (en) | 2000-03-21 |
DE69921156T2 (de) | 2005-10-13 |
GB9818916D0 (en) | 1998-10-21 |
EP1107745A1 (de) | 2001-06-20 |
ES2230884T3 (es) | 2005-05-01 |
JP2002523447A (ja) | 2002-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69921156D1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
ATE225176T1 (de) | Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie | |
ATE262336T1 (de) | Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen | |
ATE350030T1 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
DE69805202D1 (de) | Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs | |
DE60023043D1 (de) | (S,S)-Reboxetin zur Behandlung von Inkontinenz | |
DE59902314D1 (de) | Oligomerisiertes Organopolysiloxan-Cokondensat, dessen Herstellung und dessen Verwendung zur Behandlung von Oberflächen | |
DE69926385D1 (de) | Behandlung von geweben | |
DE59903921D1 (de) | Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen | |
ATE238792T1 (de) | Verwendung von makroliden zur behandlung von glaukom | |
ATE214272T1 (de) | Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz | |
DE69943089D1 (de) | Methode zur behandlung von staphylokokkeninfektionen | |
DE59707519D1 (de) | Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen | |
DE69918972D1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
DE60015791D1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
TR200200278T2 (tr) | Kalsilitik bileşimler | |
DE69924284D1 (de) | Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten | |
ATE261724T1 (de) | Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen | |
ATE251462T1 (de) | Verfahren zur behandlung von narbengewebe | |
DE69924979D1 (de) | Behandlung von chronischen schmerzen | |
DE60034110D1 (de) | Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien | |
NO984189L (no) | FremgangsmÕte for behandling av bipolar forstyrrelse | |
DE69936779D1 (de) | Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen | |
DE60128084D1 (de) | Verwendung von inaktives cln2 proenzym zur behandlung von lincl | |
DE60020591D1 (de) | Benzenoidderivate von 15-hydroxyeicosatetraensäure und verfahren zur verwendung zur behandlung des trockenen auges |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |